Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2017 Jun 1;64(11):1615-1618.
doi: 10.1093/cid/cix214.

Sofosbuvir-Daclatasvir-Simeprevir Plus Ribavirin in Direct-Acting Antiviral-Experienced Patients With Hepatitis C

Christophe Hézode  1   2 , Slim Fourati  3   2 , Stéphane Chevaliez  3   2 , Giovanna Scoazec  1 , Alexandre Soulier  3   2 , Anne Varaut  1 , Murielle François  1 , Isaac Ruiz  1   3   2 , Françoise Roudot-Thoraval  1 , Ariane Mallat  1   2 , Jean-Michel Pawlotsky  3   2
Affiliations

Sofosbuvir-Daclatasvir-Simeprevir Plus Ribavirin in Direct-Acting Antiviral-Experienced Patients With Hepatitis C

Christophe Hézode et al. Clin Infect Dis. .

Erratum in

  • Erratum.
    [No authors listed] [No authors listed] Clin Infect Dis. 2017 Oct 15;65(8):1431-1433. doi: 10.1093/cid/cix563. Clin Infect Dis. 2017. PMID: 29017252 Free PMC article. No abstract available.

Abstract

We assessed the broadly used, off-label combination of sofosbuvir, daclatasvir, simeprevir, and ribavirin in direct-acting antiviral-experienced patients, as recommended in current guidelines despite scarce data. After 24 weeks' treatment, sustained virological response 12 weeks after the end of treatment was achieved in 6 patients (60%). Two cirrhotic patients relapsed and 2 discontinued treatment due to serious adverse events.

Keywords: chronic hepatitis C; resistance; resistance-associated substitutions.; retreatment; sustained virological response.

PubMed Disclaimer

MeSH terms